Search

Your search keyword '"Griffiths, Elizabeth A."' showing total 1,286 results
Start Over Author "Griffiths, Elizabeth A."
1,286 results on '"Griffiths, Elizabeth A."'

1. Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.

Author

Xie, Zhuoer, Komrokji, Rami S, Al-Ali, Najla, Regelson, Alexandra, Geyer, Susan, Patel, Anand A, Saygin, Caner, Zeidan, Amer M, Bewersdorf, Jan Philipp, Mendez, Lourdes M, Kishtagari, Ashwin, Zeidner, Joshua F, Coombs, Catherine C, Madanat, Yazan F, Chung, Stephen S, Badar, Talha, Foran, James M, Desai, Pinkal, Tsai, Charlton, Griffiths, Elizabeth A, Al Malki, Monzr M, Amanam, Idoroenyi, Lai, Catherine, Deeg, H Joachim, Ades, Lionel, Arana-Yi, Cecilia, Osman, Afaf Eg, Dinner, Shira Naomi, Abaza, Yasmin, Taylor, Justin, Chandhok, Namrata S, Soong, Deborah, Brunner, Andrew M, Carraway, Hetty E, Singh, Abhay, Elena, Chiara, Ferrari, Jacqueline, Galli, Anna, Pozzi, Sara, Padron, Eric, Patnaik, Mrinal M, Malcovati, Luca, Savona, Michael R, and Al-Kali, Aref

Subjects
Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology, Biochemistry and cell biology, Cardiovascular medicine and haematology, Paediatrics
Abstract

Clonal cytopenia of undetermined significance (CCUS) represents a distinct disease entity characterized by myeloid-related somatic mutations with a variant allele fraction of ≥2% in individuals with unexplained cytopenia(s) but without a myeloid neoplasm (MN). Notably, CCUS carries a risk of progressing to MN, particularly in cases featuring high-risk mutations. Understanding CCUS requires dedicated studies to elucidate its risk factors and natural history. Our analysis of 357 CCUS patients investigated the interplay between clonality, cytopenia, and prognosis. Multivariate analysis identified 3 key adverse prognostic factors: the presence of splicing mutation(s) (score = 2 points), platelet count

Published
2024

4. COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.

Author

Moey, Melissa, Hennessy, Cassandra, French, Benjamin, Warner, Jeremy, Tucker, Matthew, Hausrath, Daniel, Shah, Dimpy, DeCara, Jeanne, Bakouny, Ziad, Labaki, Chris, Choueiri, Toni, Dent, Susan, Akhter, Nausheen, Ismail-Khan, Roohi, Tachiki, Lisa, Slosky, David, Polonsky, Tamar, Awosika, Joy, Crago, Audrey, Wise-Draper, Trisha, Balanchivadze, Nino, Hwang, Clara, Fecher, Leslie, Gomez, Cyndi, Hayes-Lattin, Brandon, Glover, Michael, Shah, Sumit, Gopalakrishnan, Dharmesh, Griffiths, Elizabeth, Kwon, Daniel, Koshkin, Vadim, Mahmood, Sana, Bashir, Babar, Nonato, Taylor, Razavi, Pedram, McKay, Rana, Nagaraj, Gayathri, Oligino, Eric, Puc, Matthew, Tregubenko, Polina, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Halfdanarson, Thorvardur, Farmakiotis, Dimitrios, Klein, Elizabeth, Robilotti, Elizabeth, Riely, Gregory, Durand, Jean-Bernard, Hayek, Salim, Kondapalli, Lavanya, Berg, Stephanie, OConnor, Timothy, Bilen, Mehmet, Castellano, Cecilia, Accordino, Melissa, Sibel, Blau, Weissmann, Lisa, Jani, Chinmay, Flora, Daniel, Rudski, Lawrence, Dutra, Miriam, Nathaniel, Bouganim, Ruíz-García, Erika, Vilar-Compte, Diana, Gupta, Shilpa, Morgans, Alicia, and Nohria, Anju

Subjects
COVID-19 outcomes, Cancer, Cardio-oncology, Cardiovascular disease
Abstract

BACKGROUND: Data regarding outcomes among patients with cancer and co-morbid cardiovascular disease (CVD)/cardiovascular risk factors (CVRF) after SARS-CoV-2 infection are limited. OBJECTIVES: To compare Coronavirus disease 2019 (COVID-19) related complications among cancer patients with and without co-morbid CVD/CVRF. METHODS: Retrospective cohort study of patients with cancer and laboratory-confirmed SARS-CoV-2, reported to the COVID-19 and Cancer Consortium (CCC19) registry from 03/17/2020 to 12/31/2021. CVD/CVRF was defined as established CVD or no established CVD, male ≥ 55 or female ≥ 60 years, and one additional CVRF. The primary endpoint was an ordinal COVID-19 severity outcome including need for hospitalization, supplemental oxygen, intensive care unit (ICU), mechanical ventilation, ICU or mechanical ventilation plus vasopressors, and death. Secondary endpoints included incident adverse CV events. Ordinal logistic regression models estimated associations of CVD/CVRF with COVID-19 severity. Effect modification by recent cancer therapy was evaluated. RESULTS: Among 10,876 SARS-CoV-2 infected patients with cancer (median age 65 [IQR 54-74] years, 53% female, 52% White), 6253 patients (57%) had co-morbid CVD/CVRF. Co-morbid CVD/CVRF was associated with higher COVID-19 severity (adjusted OR: 1.25 [95% CI 1.11-1.40]). Adverse CV events were significantly higher in patients with CVD/CVRF (all p

Published
2023

6. Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes—Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

Author

Aakash, Fnu, Gisriel, Savanah D., Zeidan, Amer M., Bennett, John M., Bejar, Rafael, Bewersdorf, Jan Philipp, Borate, Uma M., Boultwood, Jacqueline, Brunner, Andrew M., Buckstein, Rena, Carraway, Hetty E., Churpek, Jane E., Daver, Naval G., DeZern, Amy E., Efficace, Fabio, Fenaux, Pierre, Figueroa, Maria E., Garcia-Manero, Guillermo, Gore, Steven D., Greenberg, Peter L., Griffiths, Elizabeth A., Halene, Stephanie, Hourigan, Christopher S., Kim, Tae Kon, Kim, Nina, Komrokji, Rami S., Kutchroo, Vijay K., List, Alan F., Little, Richard F., Majeti, Ravindra, Nazha, Aziz, Nimer, Stephen D., Odenike, Olatoyosi, Padron, Eric, Patnaik, Mrinal M., Platzbecker, Uwe, Della Porta, Matteo G., Roboz, Gail J., Sallman, David A., Santini, Valeria, Sanz, Guillermo, Savona, Michael R., Sekeres, Mikkael A., Stahl, Maximilian, Starczynowski, Daniel T., Steensma, David P., Taylor, Justin, Abdel-Wahab, Omar, Wei, Andrew H., Xie, Zhuoer, Xu, Mina L., Hasserjian, Robert P., and Loghavi, Sanam

Published
2024
Full Text
View/download PDF

7. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes

Author

Komrokji, Rami S, Lanino, Luca, Ball, Somedeb, Bewersdorf, Jan P, Marchetti, Monia, Maggioni, Giulia, Travaglino, Erica, Al Ali, Najla H, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Diez-Campelo, Maria, Singh, Avani, Jain, Akriti G, Aguirre, Luis E, Tinsley-Vance, Sarah M, Schwabkey, Zaker I, Chan, Onyee, Xie, Zhouer, Brunner, Andrew M, Kuykendall, Andrew T, Bennett, John M, Buckstein, Rena, Bejar, Rafael, Carraway, Hetty E, DeZern, Amy E, Griffiths, Elizabeth A, Halene, Stephanie, Hasserjian, Robert P, Lancet, Jeffrey, List, Alan F, Loghavi, Sanam, Odenike, Olatoyosi, Padron, Eric, Patnaik, Mrinal M, Roboz, Gail J, Stahl, Maximilian, Sekeres, Mikkael A, Steensma, David P, Savona, Michael R, Taylor, Justin, Xu, Mina L, Sweet, Kendra, Sallman, David A, Nimer, Stephen D, Hourigan, Christopher S, Wei, Andrew H, Sauta, Elisabetta, D’Amico, Saverio, Asti, Gianluca, Castellani, Gastone, Delleani, Mattia, Campagna, Alessia, Borate, Uma M, Sanz, Guillermo, Efficace, Fabio, Gore, Steven D, Kim, Tae Kon, Daver, Navel, Garcia-Manero, Guillermo, Rozman, Maria, Orfao, Alberto, Wang, Sa A, Foucar, M Kathryn, Germing, Ulrich, Haferlach, Torsten, Scheinberg, Phillip, Miyazaki, Yasushi, Iastrebner, Marcelo, Kulasekararaj, Austin, Cluzeau, Thomas, Kordasti, Shahram, van de Loosdrecht, Arjan A, Ades, Lionel, Zeidan, Amer M, and Della Porta, Matteo G

Published
2024
Full Text
View/download PDF

8. Patient Advocacy Assessment in the Medicine Clerkship: A Qualitative Study of Definition, Context, and Impact

Author

Griffiths, Elizabeth P, Lai, Cindy J, Ziv, Tali, Dawson, Deanna, Dhaliwal, Gurpreet, Wheeler, Margaret, and Teherani, Arianne

Subjects
Basic Behavioral and Social Science, Behavioral and Social Science, Clinical Research, Generic health relevance, Good Health and Well Being, Clinical Clerkship, Clinical Competence, Education, Medical, Undergraduate, Humans, Patient Advocacy, Students, Medical, Advocacy, Assessment, Competency, Undergraduate medical education, Social determinants of health, Clinical Sciences, General & Internal Medicine
Abstract

BackgroundAdvocacy is a core value of the medical profession. However, patient advocacy (advocacy) is not uniformly assessed and there are no studies of the behaviors clinical supervisors consider when assessing advocacy.ObjectiveTo explore how medical students and supervisors characterize advocacy during an internal medicine clerkship, how assessment of advocacy impacted students and supervisors, and elements that support effective implementation of advocacy assessment.DesignA constructivist qualitative paradigm was used to understand advocacy assessment from the perspectives of students and supervisors.ParticipantsMedical students who completed the internal medicine clerkship at UCSF during the 2018 and 2019 academic years and supervisors who evaluated students during this period.ApproachSupervisor comments from an advocacy assessment item in the medicine clerkship and transcripts of focus groups were used to explore which behaviors students and supervisors deem to be advocacy. Separate focus groups with both students and supervisors examined the impact that advocacy assessment had on students' and supervisors' perceptions of advocacy and what additional context was necessary to effectively implement advocacy assessment.Key resultsStudents and supervisors define advocacy as identifying and addressing social determinants of health, recognizing and addressing patient wishes and concerns, navigating the health care system, conducting appropriate evaluation and treatment, and creating exceptional therapeutic alliances. Effective implementation of advocacy assessment requires the creation of non-hierarchical team environments, supervisor role modeling, and pairing assessment with teaching of advocacy skills. Inclusion of advocacy assessment reflects and dictates institutional priorities, shapes professional identity formation, and enhances advocacy skill development for students and their supervisors.ConclusionsStudents and supervisors consider advocacy to be a variety of behaviors beyond identifying and addressing social determinants of health. Effectively implementing advocacy assessment shapes students' professional identity formation, underscoring the critical importance of formally focusing on this competency in the health professions education.

Published
2022

9. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial

Author

Roboz, Gail J., Sanz, Guillermo, Griffiths, Elizabeth A., Yee, Karen, Kantarjian, Hagop, Récher, Christian, Byrne, Michael T., Patkowska, Elżbieta, Kim, Hee-Je, Thomas, Xavier, Moors, Ine, Stock, Wendy, Illés, Árpád, Fenaux, Pierre, Miyazaki, Yasushi, Yamauchi, Takahiro, O'Connell, Casey L., Hao, Yong, Keer, Harold N., Azab, Mohammad, and Döhner, Hartmut

Published
2024
Full Text
View/download PDF

10. Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study

Author

Wagner, Michael J, Hennessy, Cassandra, Beeghly, Alicia, French, Benjamin, Shah, Dimpy P, Croessmann, Sarah, Vilar-Compte, Diana, Ruiz-Garcia, Erika, Ingham, Matthew, Schwartz, Gary K, Painter, Corrie A, Chugh, Rashmi, Fecher, Leslie, Park, Cathleen, Zamulko, Olga, Trent, Jonathan C, Subbiah, Vivek, Khaki, Ali Raza, Tachiki, Lisa, Nakasone, Elizabeth S, Loggers, Elizabeth T, Labaki, Chris, Saliby, Renee Maria, McKay, Rana R, Ajmera, Archana, Griffiths, Elizabeth A, Puzanov, Igor, Tap, William D, Hwang, Clara, Tejwani, Sheela, Jhawar, Sachin R, Hayes-Lattin, Brandon, Wulff-Burchfield, Elizabeth, Kasi, Anup, Reuben, Daniel Y, Nagaraj, Gayathri, Joshi, Monika, Polimera, Hyma, Kulkarni, Amit A, Esfahani, Khashayar, Kwon, Daniel H, Paoluzzi, Luca, Bilen, Mehmet A, Durbin, Eric B, Grivas, Petros, Warner, Jeremy L, and Davis, Elizabeth J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Cancer, Prevention, Pediatric Cancer, Clinical Research, Pediatric, Pediatric Research Initiative, Aetiology, 2.4 Surveillance and distribution, Good Health and Well Being, sarcoma, COVID-19, SARS-CoV-2, CCC19, COVID-19 and Cancer Consortium, Oncology and carcinogenesis
Abstract

BackgroundPatients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19.MethodsWe performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed.Resultsof 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity.ConclusionsPatients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.

Published
2022

11. Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study

Author

Satyanarayana, Gowri, Enriquez, Kyle T, Sun, Tianyi, Klein, Elizabeth J, Abidi, Maheen, Advani, Shailesh M, Awosika, Joy, Bakouny, Ziad, Bashir, Babar, Berg, Stephanie, Bernardes, Marilia, Egan, Pamela C, Elkrief, Arielle, Feldman, Lawrence E, Friese, Christopher R, Goel, Shipra, Gomez, Cyndi Gonzalez, Grant, Keith L, Griffiths, Elizabeth A, Gulati, Shuchi, Gupta, Shilpa, Hwang, Clara, Jain, Jayanshu, Jani, Chinmay, Kaltsas, Anna, Kasi, Anup, Khan, Hina, Knox, Natalie, Koshkin, Vadim S, Kwon, Daniel H, Labaki, Chris, Lyman, Gary H, McKay, Rana R, McNair, Christopher, Nagaraj, Gayathri, Nakasone, Elizabeth S, Nguyen, Ryan, Nonato, Taylor K, Olszewski, Adam J, Panagiotou, Orestis A, Puc, Matthew, Razavi, Pedram, Robilotti, Elizabeth V, Santos-Dutra, Miriam, Schmidt, Andrew L, Shah, Dimpy P, Shah, Sumit A, Vieira, Kendra, Weissmann, Lisa B, Wise-Draper, Trisha M, Wu, Ulysses, Wu, Julie Tsu-Yu, Choueiri, Toni K, Mishra, Sanjay, Warner, Jeremy L, French, Benjamin, and Farmakiotis, Dimitrios

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Infectious Diseases, Prevention, Lung, Clinical Research, Emerging Infectious Diseases, 2.2 Factors relating to the physical environment, Aetiology, Infection, Good Health and Well Being, bacterial infections, CAPA, COVID-19, mucormycoses, viral infections, Clinical sciences, Medical microbiology
Abstract

BackgroundThe frequency of coinfections and their association with outcomes have not been adequately studied among patients with cancer and coronavirus disease 2019 (COVID-19), a high-risk group for coinfection.MethodsWe included adult (≥18 years) patients with active or prior hematologic or invasive solid malignancies and laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection, using data from the COVID-19 and Cancer Consortium (CCC19, NCT04354701). We captured coinfections within ±2 weeks from diagnosis of COVID-19, identified factors cross-sectionally associated with risk of coinfection, and quantified the association of coinfections with 30-day mortality.ResultsAmong 8765 patients (hospitalized or not; median age, 65 years; 47.4% male), 16.6% developed coinfections: 12.1% bacterial, 2.1% viral, 0.9% fungal. An additional 6.4% only had clinical diagnosis of a coinfection. The adjusted risk of any coinfection was positively associated with age >50 years, male sex, cardiovascular, pulmonary, and renal comorbidities, diabetes, hematologic malignancy, multiple malignancies, Eastern Cooperative Oncology Group Performance Status, progressing cancer, recent cytotoxic chemotherapy, and baseline corticosteroids; the adjusted risk of superinfection was positively associated with tocilizumab administration. Among hospitalized patients, high neutrophil count and C-reactive protein were positively associated with bacterial coinfection risk, and high or low neutrophil count with fungal coinfection risk. Adjusted mortality rates were significantly higher among patients with bacterial (odds ratio [OR], 1.61; 95% CI, 1.33-1.95) and fungal (OR, 2.20; 95% CI, 1.28-3.76) coinfections.ConclusionsViral and fungal coinfections are infrequent among patients with cancer and COVID-19, with the latter associated with very high mortality rates. Clinical and laboratory parameters can be used to guide early empiric antimicrobial therapy, which may improve clinical outcomes.

Published
2022

12. Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study

Author

Garcia-Manero, Guillermo, McCloskey, James, Griffiths, Elizabeth A, Yee, Karen W L, Zeidan, Amer M, Al-Kali, Aref, Deeg, H Joachim, Patel, Prapti A, Sabloff, Mitchell, Keating, Mary-Margaret, Zhu, Nancy, Gabrail, Nashat Y, Fazal, Salman, Maly, Joseph, Odenike, Olatoyosi, Kantarjian, Hagop, DeZern, Amy E, O’Connell, Casey L, Roboz, Gail J, Busque, Lambert, Buckstein, Rena, Amin, Harshad, Randhawa, Jasleen, Leber, Brian, Shastri, Aditi, Dao, Kim-Hien, Oganesian, Aram, Hao, Yong, Keer, Harold N, Azab, Mohammad, and Savona, Michael R

Published
2024
Full Text
View/download PDF

14. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.

Author

Ngai, Lok, Ma, Connie, Maguire, Orla, Do, An, Robert, Alberto, Logan, Aaron, Griffiths, Elizabeth, Nemeth, Michael, Green, Cherie, Pourmohamad, Tony, van Kuijk, Bo, Snel, Alexander, Kwidama, Zinia, Venniker-Punt, Bianca, Cooper, James, Manz, Markus, Gjertsen, Bjørn, Smit, Linda, Ossenkoppele, Gert, Janssen, Jeroen, Cloos, Jacqueline, and Sumiyoshi, Teiko

Subjects
CD34+ blasts, CLL-1, acute myeloid leukemia, bimodality, bone marrow aspirates, flow cytometry, Antigens, CD34, Biomarkers, Tumor, Bone Marrow Cells, Cytogenetic Analysis, Female, Flow Cytometry, Gene Expression Profiling, Gene Expression Regulation, Leukemic, Hematopoietic Stem Cells, Humans, Immunophenotyping, Lectins, C-Type, Leukemia, Myeloid, Acute, Male, Middle Aged, Mutation, Myeloid Cells, Precursor Cells, B-Lymphoid, Primary Cell Culture, Receptors, Mitogen
Abstract

OBJECTIVES: This study aims to retrospectively assess C-lectin-like molecule 1 (CLL-1) bimodal expression on CD34+ blasts in acute myeloid leukemia (AML) patients (total N = 306) and explore potential CLL-1 bimodal associations with leukemia and patient-specific characteristics. METHODS: Flow cytometry assays were performed to assess the deeper immunophenotyping of CLL-1 bimodality. Cytogenetic analysis was performed to characterize the gene mutation on CLL-1-negative subpopulation of CLL-1 bimodal AML samples. RESULTS: The frequency of a bimodal pattern of CLL-1 expression of CD34+ blasts ranged from 8% to 65% in the different cohorts. Bimodal CLL-1 expression was most prevalent in patients with MDS-related AML (P = .011), ELN adverse risk (P = .002), NPM1 wild type (WT, P = .049), FLT3 WT (P = .035), and relatively low percentages of leukemia-associated immunophenotypes (P = .006). Additional immunophenotyping analysis revealed the CLL-1- subpopulation may consist of pre-B cells, immature myeloblasts, and hematopoietic stem cells. Furthermore, (pre)-leukemic mutations were detected in both CLL-1+ and CLL-1- subfractions of bimodal samples (N = 3). CONCLUSIONS: C-lectin-like molecule 1 bimodality occurs in about 25% of AML patients and the CLL-1- cell population still contains malignant cells, hence it may potentially limit the effectiveness of CLL-1-targeted therapies and warrant further investigation.

Published
2021

15. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

Author

Stahl, Maximilian, Bewersdorf, Jan Philipp, Xie, Zhuoer, Porta, Matteo Giovanni Della, Komrokji, Rami, Xu, Mina L., Abdel-Wahab, Omar, Taylor, Justin, Steensma, David P., Starczynowski, Daniel T., Sekeres, Mikkael A., Sanz, Guillermo, Sallman, David A., Roboz, Gail J., Platzbecker, Uwe, Patnaik, Mrinal M., Padron, Eric, Odenike, Olatoyosi, Nimer, Stephen D., Nazha, Aziz, Majeti, Ravi, Loghavi, Sanam, Little, Richard F., List, Alan F., Kim, Tae Kon, Hourigan, Christopher S., Hasserjian, Robert P., Halene, Stephanie, Griffiths, Elizabeth A., Gore, Steven D., Greenberg, Peter, Figueroa, Maria E., Fenaux, Pierre, Efficace, Fabio, DeZern, Amy E., Daver, Naval G., Churpek, Jane E., Carraway, Hetty E., Buckstein, Rena, Brunner, Andrew M., Boultwood, Jacqueline, Borate, Uma, Bejar, Rafael, Bennett, John M., Wei, Andrew H., Santini, Valeria, Savona, Michael R., and Zeidan, Amer M.

Published
2023
Full Text
View/download PDF

17. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

Author

Fenaux, Pierre, Gobbi, Marco, Kropf, Patricia L., Issa, Jean-Pierre J., Roboz, Gail J., Mayer, Jiri, Krauter, Jürgen, Robak, Tadeusz, Kantarjian, Hagop, Novak, Jan, Jedrzejczak, Wieslaw. W., Thomas, Xavier, Ojeda-Uribe, Mario, Miyazaki, Yasushi, Min, Yoo Hong, Yeh, Su-Peng, Brandwein, Joseph, Gercheva-Kyuchukova, Liana, Demeter, Judit, Griffiths, Elizabeth, Yee, Karen, Döhner, Konstanze, Hao, Yong, Keer, Harold, Azab, Mohammad, and Döhner, Hartmut

Published
2023
Full Text
View/download PDF

18. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)

Author

Bewersdorf, Jan Philipp, Xie, Zhuoer, Bejar, Rafael, Borate, Uma, Boultwood, Jacqueline, Brunner, Andrew M., Buckstein, Rena, Carraway, Hetty E., Churpek, Jane E., Daver, Naval G., Porta, Matteo Giovanni Della, DeZern, Amy E., Fenaux, Pierre, Figueroa, Maria E., Gore, Steven D., Griffiths, Elizabeth A., Halene, Stephanie, Hasserjian, Robert P., Hourigan, Christopher S., Kim, Tae Kon, Komrokji, Rami, Kuchroo, Vijay K., List, Alan F., Loghavi, Sanam, Majeti, Ravindra, Odenike, Olatoyosi, Patnaik, Mrinal M., Platzbecker, Uwe, Roboz, Gail J., Sallman, David A., Santini, Valeria, Sanz, Guillermo, Sekeres, Mikkael A., Stahl, Maximilian, Starczynowski, Daniel T., Steensma, David P., Taylor, Justin, Abdel-Wahab, Omar, Xu, Mina L., Savona, Michael R., Wei, Andrew H., and Zeidan, Amer M.

Published
2023
Full Text
View/download PDF

19. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19:CCC19 Governance, Protocol, and Quality Assurance

Author

Abidi, Maheen, Aboulafia, David M, Accordino, Melissa K, Acoba, Jared D, Ahluwalia, Manmeet S, Ahmad, Syed A, Ajmera, Archana, Alimohamed, Saif I, Altman, Jessica, Angevine, Anne H, Bakouny, Ziad, Bar, Michael H, Bardia, Aditya, Barnholtz-Sloan, Jill S, Barrow McCollough, Briana, Bashir, Babar, Batist, Gerald, Bekaii-Saab, Tanios S, Berg, Stephanie, Bernicker, Eric H, Bhutani, Divaya, Bilen, Mehmet A, Bindal, Poorva, Bishnoi, Rohit, Blau, Sibel, Bohachek, Pamela, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bouganim, Nathaniel, Bowles, Daniel W, Busser, Fiona J, Butt, Omar, Cabal, Angelo, Cabalona, Wilhelmina D, Cabebe, Elwyn C, Caimi, Paolo, Campian, Jian L, Carducci, Theresa M, Chen, James L, Cheng, Alex, Chism, David D, Choueiri, Toni K, Clark, Melanie J, Clement, Jessica M, Connors, Jean M, Cook, Erin, Curran, Catherine R, Daher, Ahmad, Dailey, Mark E, Davis, Elizabeth J, Dawsey, Scott J, Deeken, John F, Del Prete, Salvatore A, Demetri, George D, Desai, Aakash, Doroshow, Deborah B, Durbin, Eric B, Egan, Pamela C, Elias, Rawad, Elkrief, Arielle, Elms, Destry J, Elshoury, Amro, Faller, Bryan, Farmakiotis, Dimitrios, Fecher, Leslie A, Feldman, Lawrence E, Ferrario, Cristiano, Fiala, Mark A, Flora, Daniel B, French, Benjamin, Friese, Christopher R, Fu, Julie C, Gadgeel, Shirish M, Gainor, Justin, Galsky, Matthew D, Gantt, Gerald, Garcia, Jorge A, Gartrell, Benjamin A, Gatti-Mays, Margaret E, Gill, David M, Gillaspie, Erin A, Giordano, Antonio, Glace, Mary Grace, Glover, Michael J, Goel, Sanjay, Graber, Jerome J, Griffiths, Elizabeth A, Grivas, Petros, Grover, Punita, Gulati, Anthony P, Gulati, Shuchi, Gupta, Shilpa, Gurley, Michael, Hafez, Navid, Halabi, Susan, Halfdanarson, Thorvardur R, Halmos, Balazs, Hausrath, Daniel J, and Hawley, Jessica E

Subjects
Biochemistry and Cell Biology, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Biological Sciences, Clinical Research, Cancer, COVID-19, COVID-19 Testing, Data Accuracy, Electronic Health Records, Humans, Neoplasms, Quality Improvement, SARS-CoV-2, COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org, COVID-19 and Cancer Consortium, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 institutions with >400 collaborators. More than 5,000 cases with complete baseline data have been accrued. Future directions include increased electronic health record integration for direct data ingestion, expansion to additional domestic and international sites, more intentional patient involvement, and granular analyses of still-unanswered questions related to cancer subtypes and treatments.

Published
2020

20. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Author

Kuderer, Nicole M, Choueiri, Toni K, Shah, Dimpy P, Shyr, Yu, Rubinstein, Samuel M, Rivera, Donna R, Shete, Sanjay, Hsu, Chih-Yuan, Desai, Aakash, de Lima Lopes, Gilberto, Grivas, Petros, Painter, Corrie A, Peters, Solange, Thompson, Michael A, Bakouny, Ziad, Batist, Gerald, Bekaii-Saab, Tanios, Bilen, Mehmet A, Bouganim, Nathaniel, Larroya, Mateo Bover, Castellano, Daniel, Del Prete, Salvatore A, Doroshow, Deborah B, Egan, Pamela C, Elkrief, Arielle, Farmakiotis, Dimitrios, Flora, Daniel, Galsky, Matthew D, Glover, Michael J, Griffiths, Elizabeth A, Gulati, Anthony P, Gupta, Shilpa, Hafez, Navid, Halfdanarson, Thorvardur R, Hawley, Jessica E, Hsu, Emily, Kasi, Anup, Khaki, Ali R, Lemmon, Christopher A, Lewis, Colleen, Logan, Barbara, Masters, Tyler, McKay, Rana R, Mesa, Ruben A, Morgans, Alicia K, Mulcahy, Mary F, Panagiotou, Orestis A, Peddi, Prakash, Pennell, Nathan A, Reynolds, Kerry, Rosen, Lane R, Rosovsky, Rachel, Salazar, Mary, Schmidt, Andrew, Shah, Sumit A, Shaya, Justin A, Steinharter, John, Stockerl-Goldstein, Keith E, Subbiah, Suki, Vinh, Donald C, Wehbe, Firas H, Weissmann, Lisa B, Wu, Julie Tsu-Yu, Wulff-Burchfield, Elizabeth, Xie, Zhuoer, Yeh, Albert, Yu, Peter P, Zhou, Alice Y, Zubiri, Leyre, Mishra, Sanjay, Lyman, Gary H, Rini, Brian I, Warner, Jeremy L, Consortium, COVID-19 and Cancer, Abidi, Maheen, Acoba, Jared D, Agarwal, Neeraj, Ahmad, Syed, Ajmera, Archana, Altman, Jessica, Angevine, Anne H, Azad, Nilo, Bar, Michael H, Bardia, Aditya, Barnholtz-Sloan, Jill, Barrow, Briana, Bashir, Babar, Belenkaya, Rimma, Berg, Stephanie, Bernicker, Eric H, Bestvina, Christine, Bishnoi, Rohit, Boland, Genevieve, Bonnen, Mark, Bouchard, Gabrielle, Bowles, Daniel W, Busser, Fiona, Cabal, Angelo, Caimi, Paolo, and Carducci, Theresa

Subjects
Biomedical and Clinical Sciences, Health Sciences, Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Aging, Prevention, Cancer, Lung, Good Health and Well Being, Aged, Antiviral Agents, Azithromycin, Betacoronavirus, COVID-19, Cause of Death, Comorbidity, Coronavirus Infections, Databases, Factual, Female, Humans, Hydroxychloroquine, Male, Middle Aged, Neoplasms, Pandemics, Pneumonia, Viral, Prognosis, Risk Factors, SARS-CoV-2, COVID-19 Drug Treatment, COVID-19 and Cancer Consortium, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundData on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness.MethodsIn this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing.FindingsOf 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57-76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 1·53-2·21), male sex (1·63, 1·07-2·48), smoking status (former smoker vs never smoked: 1·60, 1·03-2·47), number of comorbidities (two vs none: 4·50, 1·33-15·28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3·89, 2·11-7·18), active cancer (progressing vs remission: 5·20, 2·77-9·77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79-4·79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07-0·84) or the US-Midwest (0·50, 0·28-0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality.InterpretationAmong patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments.FundingAmerican Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.

Published
2020

22. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes

Author

Zeidan, Amer M., Bewersdorf, Jan Philipp, Buckstein, Rena, Sekeres, Mikkael A., Steensma, David P., Platzbecker, Uwe, Loghavi, Sanam, Boultwood, Jacqueline, Bejar, Rafael, Bennett, John M., Borate, Uma, Brunner, Andrew M., Carraway, Hetty, Churpek, Jane E., Daver, Naval G., Della Porta, Matteo, DeZern, Amy E., Efficace, Fabio, Fenaux, Pierre, Figueroa, Maria E., Greenberg, Peter, Griffiths, Elizabeth A., Halene, Stephanie, Hasserjian, Robert P., Hourigan, Christopher S., Kim, Nina, Kim, Tae Kon, Komrokji, Rami S., Kutchroo, Vijay, List, Alan F., Little, Richard F., Majeti, Ravi, Nazha, Aziz, Nimer, Stephen D., Odenike, Olatoyosi, Padron, Eric, Patnaik, Mrinal M., Roboz, Gail J., Sallman, David A., Sanz, Guillermo, Stahl, Maximilian, Starczynowski, Daniel T., Taylor, Justin, Xie, Zhuoer, Xu, Mina, Savona, Michael R., Wei, Andrew H., Abdel-Wahab, Omar, and Santini, Valeria

Published
2022
Full Text
View/download PDF

24. Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium

Author

Choueiri, Toni K., Labaki, Chris, Bakouny, Ziad, Hsu, Chih-Yuan, Schmidt, Andrew L., de Lima Lopes, Gilberto, Jr., Hwang, Clara, Singh, Sunny R.K., Jani, Chinmay, Weissmann, Lisa B., Griffiths, Elizabeth A., Halabi, Susan, Wu, Ulysses, Berg, Stephanie, O'Connor, Timothy E., Wise-Draper, Trisha M., Panagiotou, Orestis A., Klein, Elizabeth J., Joshi, Monika, Yared, Fares, Dutra, Miriam Santos, Gatson, Na Tosha N., Blau, Sibel, Singh, Harpreet, Nanchal, Rahul, McKay, Rana R., Nonato, Taylor K., Quinn, Ryann, Rubinstein, Samuel M., Puc, Matthew, Mavromatis, Blanche H., Vikas, Praveen, Faller, Bryan, Zaren, Howard A., Del Prete, Salvatore, Russell, Karen, Reuben, Daniel Y., Accordino, Melissa K., Friese, Christopher R., Mishra, Sanjay, Rivera, Donna R., Shyr, Yu, Farmakiotis, Dimitrios, and Warner, Jeremy L.

Published
2023
Full Text
View/download PDF

25. Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy

Author

Versluis, Jurjen, Pandey, Manu, Flamand, Yael, Haydu, J. Erika, Belizaire, Roger, Faber, Mark, Vedula, Rahul S., Charles, Anne, Copson, Kevin M., Shimony, Shai, Rozental, Alon, Bendapudi, Pavan K., Wolach, Ofir, Griffiths, Elizabeth A., Thompson, James E., Stone, Richard M., DeAngelo, Daniel J., Neuberg, Donna, Luskin, Marlise R., Wang, Eunice S., and Lindsley, R. Coleman

Published
2022
Full Text
View/download PDF

26. Immune Checkpoint Inhibitor Therapy and Associations with Clonal Hematopoiesis †.

Author

Singh, Abhay, Trinchant, Nuria Mencia, Mishra, Rahul, Arora, Kirti, Mehta, Smit, Kuzmanovic, Teodora, Zokaei Nikoo, Maedeh, Singh, Inderpreet, Przespolewski, Amanda C., Swaminathan, Mahesh, Ernstoff, Marc S., Dy, Grace K., Yan, Lunbiao, Sinha, Eti, Sharma, Shruti, Hassane, Duane C., Griffiths, Elizabeth A., Wang, Eunice, Guzman, Monica L., and Thota, Swapna

Subjects
NON-small-cell lung carcinoma, HEMATOPOIETIC stem cells, IMMUNE checkpoint inhibitors, IMMUNE checkpoint proteins, EXPOSURE therapy
Abstract

Cancer cohorts are now known to be associated with increased rates of clonal hematopoiesis (CH). We sort to characterize the hematopoietic compartment of patients with melanoma and non-small cell lung cancer (NSCLC) given our recent population level analysis reporting evolving rates of secondary leukemias. The advent of immune checkpoint blockade (ICB) has dramatically changed our understanding of cancer biology and has altered the standards of care for patients. However, the impact of ICB on hematopoietic myeloid clonal expansion remains to be determined. We studied if exposure to ICB therapy affects hematopoietic clonal architecture and if their evolution contributed to altered hematopoiesis. Blood samples from patients with melanoma and NSCLC (n = 142) demonstrated a high prevalence of CH. Serial samples (or post ICB exposure samples; n = 25) were evaluated in melanoma and NSCLC patients. Error-corrected sequencing of a targeted panel of genes recurrently mutated in CH was performed on peripheral blood genomic DNA. In serial sample analysis, we observed that mutations in DNMT3A and TET2 increased in size with longer ICB exposures in the melanoma cohort. We also noted that patients with larger size DNMT3A mutations with further post ICB clone size expansion had longer durations of ICB exposure. All serial samples in this cohort showed a statistically significant change in VAF from baseline. In the serial sample analysis of NSCLC patients, we observed similar epigenetic expansion, although not statistically significant. Our study generates a hypothesis for two important questions: (a) Can DNMT3A or TET2 CH serve as predictors of a response to ICB therapy and serve as a novel biomarker of response to ICB therapy? (b) As ICB-exposed patients continue to live longer, the myeloid clonal expansion may portend an increased risk for subsequent myeloid malignancy development. Until now, the selective pressure of ICB/T-cell activating therapies on hematopoietic stem cells were less known and we report preliminary evidence of clonal expansion in epigenetic modifier genes (also referred to as inflammatory CH genes). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Brief Report: Impact of anti-cancer treatments on outcomes of COVID-19 in patients with thoracic cancers: a CCC19 registry analysis

Author

Kulkarni, Amit A., primary, Hennessy, Cassandra, additional, Wislon, Grace, additional, Ramesh, Vidhyalakshmi, additional, Hwang, Clara, additional, Joy, Awosika, additional, Bakouny, Ziad, additional, Khan, Hina, additional, Vilar-Compte, Diana, additional, McKay, Rana, additional, Jani, Chinmay, additional, Weissmann, Lisa, additional, Griffiths, Elizabeth, additional, Batist, Gerald, additional, Bouganim, Nathaniel, additional, Mavromatis, Blanche, additional, Bashir, Babar, additional, Nguyen, Ryan H., additional, Riess, Jonathan W., additional, Puc, Matthew, additional, Kasi, Anup, additional, Berg, Stephanie, additional, Castillo, Dan Ran, additional, Hayes-Lattin, Brandon, additional, Hosmer, Wylie, additional, Flora, Daniel, additional, Mishra, Sanjay, additional, French, Benjamin, additional, Warner, Jeremy L., additional, Lopes, Gilberto, additional, Peters, Solange, additional, and Florez, Narjust, additional

Published
2024
Full Text
View/download PDF

31. Germline variants drive myelodysplastic syndrome in young adults

Author

Feurstein, Simone, Churpek, Jane E., Walsh, Tom, Keel, Sioban, Hakkarainen, Marja, Schroeder, Thomas, Germing, Ulrich, Geyh, Stefanie, Heuser, Michael, Thol, Felicitas, Pohlkamp, Christian, Haferlach, Torsten, Gao, Juehua, Owen, Carolyn, Goehring, Gudrun, Schlegelberger, Brigitte, Verma, Divij, Krause, Daniela S., Gao, Guimin, Cronin, Tara, Gulsuner, Suleyman, Lee, Ming, Pritchard, Colin C., Subramanian, Hari Prasanna, del Gaudio, Daniela, Li, Zejuan, Das, Soma, Kilpivaara, Outi, Wartiovaara-Kautto, Ulla, Wang, Eunice S., Griffiths, Elizabeth A., Döhner, Konstanze, Döhner, Hartmut, King, Mary-Claire, and Godley, Lucy A.

Published
2021
Full Text
View/download PDF

33. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts

Author

Zeidan, Amer M, Boddu, Prajwal C, Patnaik, Mrinal M, Bewersdorf, Jan Philipp, Stahl, Maximilian, Rampal, Raajit K, Shallis, Rory, Steensma, David P, Savona, Michael R, Sekeres, Mikkael A, Roboz, Gail J, DeAngelo, Daniel J, Schuh, Andre C, Padron, Eric, Zeidner, Joshua F, Walter, Roland B, Onida, Francesco, Fathi, Amir, DeZern, Amy, Hobbs, Gabriela, Stein, Eytan M, Vyas, Paresh, Wei, Andrew H, Bowen, David T, Montesinos, Pau, Griffiths, Elizabeth A, Verma, Amit K, Keyzner, Alla, Bar-Natan, Michal, Navada, Shyamala C, Kremyanskaya, Marina, Goldberg, Aaron D, Al-Kali, Aref, Heaney, Mark L, Nazha, Aziz, Salman, Huda, Luger, Selina, Pratz, Keith W, Konig, Heiko, Komrokji, Rami, Deininger, Michael, Cirici, Blanca Xicoy, Bhatt, Vijaya Raj, Silverman, Lewis R, Erba, Harry P, Fenaux, Pierre, Platzbecker, Uwe, Santini, Valeria, Wang, Eunice S, Tallman, Martin S, Stone, Richard M, and Mascarenhas, John

Published
2020
Full Text
View/download PDF

35. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial

Author

Roboz, Gail J., primary, Sanz, Guillermo F., additional, Griffiths, Elizabeth A, additional, Yee, Karen W.L., additional, Kantarjian, Hagop M, additional, Récher, Christian, additional, Byrne, Michael T., additional, Patkowska, Elzbieta, additional, Kim, Hee Je, additional, Thomas, Xavier, additional, Moors, Ine, additional, Stock, Wendy, additional, Illes, Arpad, additional, Fenaux, Pierre, additional, Miyazaki, Yasushi, additional, Yamauchi, Takahiro, additional, O'Connell, Casey, additional, Hao, Yong, additional, Keer, Harold Neal, additional, Azab, Mohammad, additional, and Döhner, Hartmut, additional

Published
2024
Full Text
View/download PDF

38. Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia

Author

Wang, Youjin, Zhou, Weiyin, McReynolds, Lisa J., Katki, Hormuzd A., Griffiths, Elizabeth A., Thota, Swapna, Machiela, Mitchell J., Yeager, Meredith, McCarthy, Philip, Pasquini, Marcelo, Wang, Junke, Karaesmen, Ezgi, Rizvi, Abbas, Preus, Leah, Tang, Hancong, Wang, Yiwen, Pooler, Loreall, Sheng, Xin, Haiman, Christopher A., Van Den Berg, David, Spellman, Stephen R., Wang, Tao, Kuxhausen, Michelle, Chanock, Stephen J., Lee, Stephanie J., Hahn, Theresa E., Sucheston-Campbell, Lara E., and Gadalla, Shahinaz M.

Published
2021
Full Text
View/download PDF

40. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Author

Garcia-Manero, Guillermo, Roboz, Gail, Walsh, Katherine, Kantarjian, Hagop, Ritchie, Ellen, Kropf, Patricia, O'Connell, Casey, Tibes, Raoul, Lunin, Scott, Rosenblat, Todd, Yee, Karen, Stock, Wendy, Griffiths, Elizabeth, Mace, Joseph, Podoltsev, Nikolai, Berdeja, Jesus, Jabbour, Elias, Issa, Jean-Pierre J, Hao, Yong, Keer, Harold N, Azab, Mohammad, and Savona, Michael R

Published
2019
Full Text
View/download PDF

41. The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study.

Author

Castellano, Cecilia A., Sun, Tianyi, Ravindranathan, Deepak, Hwang, Clara, Balanchivadze, Nino, Singh, Sunny R. K., Griffiths, Elizabeth A., Puzanov, Igor, Ruiz‐Garcia, Erika, Vilar‐Compte, Diana, Cárdenas‐Delgado, Ana I., McKay, Rana R., Nonato, Taylor K., Ajmera, Archana, Yu, Peter P., Nadkarni, Rajani, O'Connor, Timothy E., Berg, Stephanie, Ma, Kim, and Farmakiotis, Dimitrios

Subjects
METASTASIS, COVID-19, CANCER prognosis, COHORT analysis, INTENSIVE care units
Abstract

Background: COVID‐19 can have a particularly detrimental effect on patients with cancer, but no studies to date have examined if the presence, or site, of metastatic cancer is related to COVID‐19 outcomes. Methods: Using the COVID‐19 and Cancer Consortium (CCC19) registry, the authors identified 10,065 patients with COVID‐19 and cancer (2325 with and 7740 without metastasis at the time of COVID‐19 diagnosis). The primary ordinal outcome was COVID‐19 severity: not hospitalized, hospitalized but did not receive supplemental O2, hospitalized and received supplemental O2, admitted to an intensive care unit, received mechanical ventilation, or died from any cause. The authors used ordinal logistic regression models to compare COVID‐19 severity by presence and specific site of metastatic cancer. They used logistic regression models to assess 30‐day all‐cause mortality. Results: Compared to patients without metastasis, patients with metastases have increased hospitalization rates (59% vs. 49%) and higher 30 day mortality (18% vs. 9%). Patients with metastasis to bone, lung, liver, lymph nodes, and brain have significantly higher COVID‐19 severity (adjusted odds ratios [ORs], 1.38, 1.59, 1.38, 1.00, and 2.21) compared to patients without metastases at those sites. Patients with metastasis to the lung have significantly higher odds of 30‐day mortality (adjusted OR, 1.53; 95% confidence interval, 1.17–2.00) when adjusting for COVID‐19 severity. Conclusions: Patients with metastatic cancer, especially with metastasis to the brain, are more likely to have severe outcomes after COVID‐19 whereas patients with metastasis to the lung, compared to patients with cancer metastasis to other sites, have the highest 30‐day mortality after COVID‐19. Patients with metastatic cancer have more severe outcomes than patients without metastasis, with those with metastasis to the brain having the highest odds of severe COVID‐19. When adjusting for initial COVID‐19 severity, patients with metastasis to the lung, compared to patients with metastasis sites other than the lung, have the highest odds of 30‐day mortality. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Volume 6, Issue 1 (2023) Criminal Justice Agents and Responsibility

Author

Berryessa, Colleen, primary, Griffiths, Elizabeth, additional, Hubbard, Kaitlen, additional, Isom, Deena A, additional, Kaplun, Kateryna, additional, Li, Hiuxuan, additional, Liu, Siyu, additional, Nir, Esther, additional, Scheuerman, Heather L., additional, Schumann, Rachel, additional, Xie, Sandy, additional, and Yule, Carolyn, additional

Published
2023
Full Text
View/download PDF

43. English as a medium of instruction in higher education institutions in Norway : a critical exploratory study of lecturers' perspectives and practices

Author

Griffiths, Elizabeth Joyce, Troudi, Salah, and Larkin, Shirley

Subjects
378, English as a Medium of Instruction, critical applied linguistics, linguistic imperialism, domain loss, internationalism, globalisation, commodification of education
Abstract

This critical exploratory study investigates the perceptions and practices of Norwegian lecturers on the implementation of a policy of English as a Medium of Instruction (EMI) at their Higher Education Institution (HEI). It focuses on their attitudes towards English usage, how they have been prepared and cope in the classroom, and looks at their language and pedagogic competences. The socio-cultural context of using English inside and outside the auditorium is explored and leads to questions of Anglo/American influence and Norwegian domain loss. The study is informed by critical Applied Linguistics (CALx), linguistic imperialism and Bourdieu’s theories on social capital and power. It examines teaching through critical pedagogy and Vygotsky’s socio-cultural theory of learning to aid understanding of classroom engagement and communication, and successful learning. This study has been informed by the critical approach to challenge normative assumptions of the use of EMI. Qualitative methods were used to collect data; twenty Norwegian teaching academics were interviewed, of whom five were observed whilst teaching. Careful coding and analysis of the data revealed surprising attitudes and perceptions varying from enthusiasm to anxiety for EMI. The participants generally accepted the top-down decision making by the administration on the increase of EMI and English usage. The influences of globalisation and commodification at HEIs combined with the rapid increase in English usage seem to have led to increased power of the management and bureaucratization. Some participants, mostly from the humanities, felt they lacked voice and agency in the implementation and their preparation for EMI, whilst some from the sciences actively embraced English and some wanted English as the working language in HEIs. There was a general feeling that more time and language resources were needed for professional development to cope with the change to EMI. All the participants worked hard to succeed in EMI; they were aiming at NS language competencies and wanted to be better at grammar, pronunciation and terminology, but seemed unaware of the pragmatic level of communication required for teaching and did not recognise the necessity of pedagogic training for EMI. There was a lack of dialogic teaching making co-constructed learning challenging and transformative pedagogy more difficult to achieve. They adapted to the multi-cultural/lingual classroom in a pragmatic manner, but were not given spaces for counter-pedagogies, critical pedagogy and the ideals of the transformative intellectual. The research reveals five areas of concern: a) inadequate English language at the pragmatic level for the demands of EMI, b) inadequate pedagogic skills for the multi-lingual and cultural classroom, c) concern over local and international students’ level of English, d) standardized, Anglo/American teaching materials leading to a lack of diversity and critical approaches, and e) the threat to academic Norwegian from international academics not learning Norwegian, the publishing reward system at Norwegian HEIs and the perceived status of English, and the resultant decline in dissemination to the general public. However juxtaposed to the above points, most participants experienced the international classroom positively and were well-received by and pleased to be in their academic Community of Practice resulting generally in an ambivalent attitude to EMI.

Published
2013

47. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

Author

Zeidan, Amer M., Platzbecker, Uwe, Bewersdorf, Jan Philipp, Stahl, Maximilian, Adès, Lionel, Borate, Uma, Bowen, David, Buckstein, Rena, Brunner, Andrew, Carraway, Hetty E., Daver, Naval, Díez-Campelo, Maria, de Witte, Theo, DeZern, Amy E., Efficace, Fabio, Garcia-Manero, Guillermo, Garcia, Jacqueline S., Germing, Ulrich, Giagounidis, Aristoteles, Griffiths, Elizabeth A., Hasserjian, Robert P., Hellström-Lindberg, Eva, Iastrebner, Marcelo, Komrokji, Rami, Kulasekararaj, Austin G., Malcovati, Luca, Miyazaki, Yasushi, Odenike, Olatoyosi, Santini, Valeria, Sanz, Guillermo, Scheinberg, Phillip, Stauder, Reinhard, van de Loosdrecht, Arjan A., Wei, Andrew H., Sekeres, Mikkael A., Fenaux, Pierre, Hematology, AII - Cancer immunology, AII - Inflammatory diseases, and CCA - Cancer biology and immunology

Subjects
All institutes and research themes of the Radboud University Medical Center, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
Abstract

Contains fulltext : 292382.pdf (Publisher’s version ) (Closed access) Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable clinical presentations and outcomes. The initial response criteria developed by the International Working Group (IWG) in 2000 have been used in clinical practice, clinical trials, regulatory reviews, and drug labels. Although the IWG criteria were revised in 2006 and 2018 (the latter focusing on lower-risk disease), limitations persist in their application to higher-risk MDS (HR-MDS) and their ability to fully capture the clinical benefits of novel investigational drugs or serve as valid surrogates for longer-term clinical end points (eg, overall survival). Further, issues related to the ambiguity and practicality of some criteria lead to variability in interpretation and interobserver inconsistency in reporting results from the same sets of data. Thus, we convened an international panel of 36 MDS experts and used an established modified Delphi process to develop consensus recommendations for updated response criteria that would be more reflective of patient-centered and clinically relevant outcomes in HR-MDS. Among others, the IWG 2023 criteria include changes in the hemoglobin threshold for complete remission (CR), the introduction of CR with limited count recovery and CR with partial hematologic recovery as provisional response criteria, the elimination of marrow CR, and specific recommendations for the standardization of time-to-event end points and the derivation and reporting of responses. The updated criteria should lead to a better correlation between patient-centered outcomes and clinical trial results in an era of multiple emerging new agents with novel mechanisms of action.

Published
2023
Full Text
View/download PDF

48. Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia

Author

Awada, Hassan, primary, Abdelmalek, Mina, additional, Cronin, Tara, additional, Baron, Jeffrey, additional, Kashour, Zakariya, additional, Azad, Farhan, additional, Faisal, Muhammad Salman, additional, Faber, Mark, additional, Gravina, Matthew, additional, Sung, Pamela J., additional, Green, Steven D., additional, Przespolewski, Amanda, additional, Thompson, James E., additional, Griffiths, Elizabeth A., additional, and Wang, Eunice S., additional

Published
2023
Full Text
View/download PDF

49. POSTER: MDS-634 Efficacy and Safety of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subpopulation from Phase 2 and ASCERTAIN Phase 3 Studies

Author

Savona, Michael R., primary, McCloskey, James K., additional, Griffiths, Elizabeth A., additional, Yee, Karen W.L., additional, Zeidan, Amer M., additional, Al-Kali, Aref, additional, Deeg, H. Joachim, additional, Patel, Prapti A., additional, Sabloff, Mitchell, additional, Keating, Mary-Margaret, additional, Zhu, Nancy, additional, Gabrail, Nashat, additional, Fazal, Salman, additional, Maly, Joseph, additional, Odenike, Olatoyosi, additional, Kantarjian, Hagop M., additional, DeZern, Amy E., additional, O'Connell, Casey L., additional, Roboz, Gail J., additional, Busque, Lambert, additional, Buckstein, Rena, additional, Amin, Harshad, additional, Randhawa, Jasleen K., additional, Leber, Brian, additional, Dao, Kim-Hien, additional, Sano, Yuri, additional, Mirakhur, Beloo, additional, Chan, Winny, additional, Oganesian, Aram, additional, Keer, Harold, additional, and Garcia-Manero, Guillermo, additional

Published
2023
Full Text
View/download PDF

50. MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis

Author

Garcia-Manero, Guillermo, primary, Bachiashvili, Kimo, additional, Griffiths, Elizabeth A., additional, Zeidan, Amer M., additional, Traer, Elie, additional, Saini, Lalit, additional, Amin, Harshad, additional, Mohan, Sanjay, additional, Lubbert, Michael, additional, Maness-Harris, Lori, additional, Foran, James, additional, Selleslag, Dominik, additional, Xicoy, Blanca, additional, Pollyea, Daniel A., additional, Sallman, David A., additional, Al-Kali, Aref, additional, Berdeja, Jesus G., additional, Al-Ali, Haifa, additional, Zhu, Nancy Y., additional, Lopez, Patricia Font, additional, Santillana, Guillermo Sanz, additional, Santini, Valeria, additional, Yimer, Habte, additional, Cripe, Larry D., additional, Priego, Victor, additional, Odenike, Olatoyosi, additional, Heyrman, Bert, additional, Ferreiras, David Valcarcel, additional, Vachhni, Pankit J, additional, Chan, Winny, additional, Sano, Yuri, additional, Mirakhur, Beloo, additional, Oganesian, Aram, additional, Keer, Harold, additional, and Yacoub, Abdulraheem, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results